Skip to main content

STERIS plc stock price and financials

  • STE · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$264.32+4.29%Close 13 Nov 2026
EV / EBITDA
16.24
Beta · 1 year
0.41
Return · 1 year
−1.4%
52-week range$195.14 — $269.44

Share price close 16 Nov 2026

+17.8%1 monthHigh $264.32Low $221.48
$220$240$260$280Q2 FY2027 report filed 5 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+24.6%6 monthsHigh $264.32Low $199.40
$180$200$220$240$260$280Q4 FY2026 report filed 29 May 2026Q1 FY2027 report filed 7 Aug 2026Q2 FY2027 report filed 5 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+4.2%year to dateHigh $268.65Low $199.40
$180$200$220$240$260$280Q3 FY2026 report filed 6 Feb 2026Q4 FY2026 report filed 29 May 2026Q1 FY2027 report filed 7 Aug 2026Q2 FY2027 report filed 5 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+2.3%1 yearHigh $268.65Low $199.40
$180$200$220$240$260$280Q3 FY2026 report filed 6 Feb 2026Q4 FY2026 report filed 29 May 2026Q1 FY2027 report filed 7 Aug 2026Q2 FY2027 report filed 5 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+29.8%3 yearsHigh $268.65Low $197.44
$180$200$220$240$260$280Q3 FY2024 report filed 8 Feb 2024Q4 FY2024 report filed 29 May 2024Q1 FY2025 report filed 8 Aug 2024Q2 FY2025 report filed 7 Nov 2024Q3 FY2025 report filed 7 Feb 2025Q4 FY2025 report filed 29 May 2025Q1 FY2026 report filed 7 Aug 2025Q2 FY2026 report filed 6 Nov 2025Q3 FY2026 report filed 6 Feb 2026Q4 FY2026 report filed 29 May 2026Q1 FY2027 report filed 7 Aug 2026Q2 FY2027 report filed 5 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+299%10 yearsHigh $268.65Low $65.05
$0$100$200$300Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

STERIS plc reported revenue of $5.94 billion for fiscal year 2026 (the twelve months to 31 Mar 2026), up 8.7% from fiscal 2025. Net income was $782 million and diluted earnings per share $7.93.

In its latest reported quarter, the second quarter of fiscal 2027 (the three months to 30 Sep 2026), revenue was $1.59 billion, up 8.8% from a year earlier.

Figures from STERIS plc's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 5 Nov 2026.

Revenue FY2026
$5.94B+8.7%
Net income
$782.3M+27.3%
Diluted EPS
$7.93+27.9%
Gross margin
44.2%+0.2 pts
Free cash flow
$972.4M+25.0%
Net debt
$1.65B−18.9%

Fiscal 2026 against fiscal 2025; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2017–2026

  • Revenue
  • Net income
$0$2B$4B$6BRevenue, FY17: $2.61BNet income, FY17: $109.97MFY17Revenue, FY18: $2.62BNet income, FY18: $290.92MFY18Revenue, FY19: $2.78BNet income, FY19: $303.72MFY19Revenue, FY20: $3.03BNet income, FY20: $407.66MFY20Revenue, FY21: $3.11BNet income, FY21: $397.4MFY21Revenue, FY22: $4.22BNet income, FY22: $243.89MFY22Revenue, FY23: $4.54BNet income, FY23: $107.03MFY23Revenue, FY24: $5.14BNet income, FY24: $378.2MFY24Revenue, FY25: $5.46BNet income, FY25: $614.6MFY25Revenue, FY26: $5.94BNet income, FY26: $782.3MFY26

Latest quarter · Q2 FY2027 to 30 Sep 2026, filed 5 Nov 2026 · Full results →

Revenue
$1.59B+8.8% on a year
Gross margin
44.7%+0.5 pts on a year
Operating income
$294.3M+10.7% on a year
Net income
$213.7M+11.4% on a year
Diluted EPS
$2.19+12.9% on a year
Free cash flow
$212.9M+5.8% on a year

Comparable companies All of Health Care →

STERIS plc beside the other S&P 500 members in Health Care Equipment, by market value.

STERIS plc and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
SterisSTE—+4.3%−1.4%———
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2017–2026

  • Gross
  • Operating
  • Net
0%20%40%60%44.2%18.6%13.2%FY17FY20FY23FY26

STERIS plc revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

STERIS plc revenue by segment, by fiscal year
RevenueFY 2023FY 2024FY 2025FY 2026
Healthcare$3.09B$3.61B+17.1%$3.88B+7.4%$4.21B+8.5%
AST$914.4M$954.0M+4.3%$1.04B+8.9%$1.14B+9.6%
Life Sciences:$536.7M$571.7M+6.5%$542.3M−5.1%$588.8M+8.6%
Total revenue$4.54B$5.14B$5.46B$5.94B

By product

STERIS plc revenue by product, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025FY 2026
Product$2.19B$2.36B+7.7%$2.76B+16.9%$2.87B+3.9%$3.06B+6.6%
Service$2.03B$2.17B+7.1%$2.37B+9.3%$2.59B+9.0%$2.88B+11.1%
Total revenue$4.22B$4.54B$5.14B$5.46B$5.94B

By region

STERIS plc revenue by region, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025FY 2026
United States$2.94B$3.25B+10.5%$3.75B+15.3%$4.01B+6.8%$4.33B+8.1%
Other locations$1.20B$1.21B+0.8%$1.30B+8.0%$1.34B+3.1%$1.49B+11.1%
Ireland$81.86M$74.29M−9.2%$82.70M+11.3%$107.3M+29.7%$108.5M+1.1%
Total revenue$4.22B$4.54B$5.14B$5.46B$5.94B

Financial statements

Fiscal years, the latest ending 31 Mar 2026. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

STERIS plc income statement, annual
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Revenue$2.61B$2.62B$2.78B$3.03B$3.11B$4.22B$4.54B$5.14B$5.46B$5.94B
Revenue growth—+0.3%+6.2%+8.9%+2.5%+35.9%+7.4%+13.3%+6.2%+8.7%
Gross profit$1.03B$1.09B$1.17B$1.32B$1.34B$1.88B$1.98B$2.22B$2.40B$2.63B
Operating income$226.2M$399.9M$411.0M$537.0M$548.4M$477.8M$791.1M$836.1M$866.6M$1.10B
Net income$110.0M$290.9M$303.7M$407.7M$397.4M$243.9M$107.0M$378.2M$614.6M$782.3M
Diluted EPS$1.28$3.39$3.55$4.76$4.63$2.48$1.07$3.81$6.20$7.93
Gross margin39.3%41.7%42.2%43.6%43.2%44.6%43.7%43.2%44.0%44.2%
Operating margin8.7%15.3%14.8%17.7%17.6%11.3%17.4%16.3%15.9%18.6%
Net margin4.2%11.1%10.9%13.5%12.8%5.8%2.4%7.4%11.3%13.2%

Cash flow

STERIS plc cash flow, annual
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Operating cash flow$424.1M$457.6M$539.5M$590.6M$689.6M$684.8M$756.9M$973.3M$1.15B$1.34B
Capital expenditure$172.9M$165.5M$189.7M$214.5M$239.3M$287.6M$362.0M$360.3M$370.1M$369.0M
Free cash flow$251.2M$292.2M$349.8M$376.0M$450.4M$397.2M$395.0M$613.0M$778.0M$972.4M

Balance sheet and shares

STERIS plc balance sheet and shares, annual
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Cash and equivalents$282.9M$201.5M$220.6M$319.6M$220.5M$348.3M$208.4M$207.0M$171.7M$439.6M
Total debt—$1.32B$1.18B$1.15B$1.80B$3.28B$3.25B$3.38B$2.20B$2.09B
Shareholders' equity$2.81B$3.21B$3.18B$3.41B$3.88B$6.53B$6.08B$6.30B$6.60B$7.18B
Diluted shares86.1M85.7M85.5M85.6M85.9M98.3M100M99.4M99.1M98.7M
Dividends per share$1.09$1.21$1.33$1.45$1.57$1.69$1.84$2.03$2.23$2.46

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

STERIS plc quarterly financial figures
PeriodQ3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027Q2 FY2027
Revenue$1.37B$1.48B$1.39B$1.46B$1.50B$1.59B$1.49B$1.59B
Revenue, year on year+5.6%+4.3%+8.7%+9.9%+9.2%+7.3%+7.3%+8.8%
Gross margin44.5%43.3%45.1%44.2%43.8%43.9%45.8%44.7%
Operating income$245.3M$216.1M$246.0M$265.8M$273.2M$316.8M$285.8M$294.3M
Net income$173.5M$145.6M$177.4M$191.9M$192.9M$220.2M$200.1M$213.7M
Diluted EPS$1.75$1.48$1.79$1.94$1.96$2.24$2.04$2.19
Free cash flow$243.6M$189.9M$326.4M$201.3M$199.5M$245.2M$279.6M$212.9M

Operating KPIs

The operating figures STERIS plc reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

STERIS plc operating KPIs
KPILatestPeriodChange on a yearRecent periods
Product revenue$816.9Mquarter to 30 Sep 2026up 9.6%
Service revenue$771.7Mquarter to 30 Sep 2026up 7.9%
Capital equipment revenue$1.7Mquarter to 30 Sep 2026down 19.0%
Healthcare revenue$1.1Bquarter to 30 Sep 2026up 8.6%
AST revenue$295.6Mquarter to 30 Sep 2026up 5.0%
Life Sciences (revenue)$170.6Mquarter to 30 Sep 2026up 17.7%
United States revenue$1.2Bquarter to 30 Sep 2026up 9.2%
Ireland revenue$26.0Mquarter to 30 Sep 2026down 4.8%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was STERIS plc's revenue in fiscal 2026?

$5.94 billion for fiscal year 2026 (the twelve months to 31 Mar 2026), as reported in its annual report.

What was STERIS plc's net income in fiscal 2026?

$782 million for fiscal year 2026 (the twelve months to 31 Mar 2026).

What were STERIS plc's diluted earnings per share in fiscal 2026?

$7.93 for fiscal year 2026 (the twelve months to 31 Mar 2026).

What is STERIS plc's gross margin?

44.2% for fiscal year 2026 (the twelve months to 31 Mar 2026): gross profit divided by revenue.

What is STERIS plc's operating margin?

18.6% for fiscal year 2026 (the twelve months to 31 Mar 2026): operating income divided by revenue.

How much free cash flow did STERIS plc generate in fiscal 2026?

$972 million for fiscal year 2026 (the twelve months to 31 Mar 2026): operating cash flow less capital expenditure.

Where does STERIS plc's revenue come from?

In fiscal 2026, by segment: Healthcare $4.21B (71%), AST $1.14B (19%), Life Sciences: $588.8M (9.9%), out of $5.94B in all, as stated in its annual report.

In the terminal

Twenty years of STERIS plc's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans